Evidence map›Paper›PMID 15906165›Full record

ArticlePharmaceutical research2005

Intracellular delivery of Bak BH3 peptide by microbubble-enhanced ultrasound.

Manabu Kinoshita, Kullervo Hynynen

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Ultrasound imaging beyond the vasculature with new generation contrast agents.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Manabu KinoshitaDepartment of Radiology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA. mkinosit@bwh.harvard.edu
Kullervo Hynynen
Brigham and Women's Hospital · US

Funding

Ultrasound Therapy Delivery Through Intact SkullR01EB003268 · NIBIB · SUNNYBROOK & WOMEN'S COLL HLTH SCIS CTR · PI HYNYNEN, KULLERVO · 2003 to 2020
$8.2M
NIBIB NIH HHS R01 EB 003268
6 · The paper itself

Abstract

purposeTo investigate the possibility of intracellular delivery of Bak BH3 peptide using sonoporation effect by microbubble-enhanced ultrasound.

methodsHeLa and BJAB cells were exposed to 1.696-Mhz focused ultrasound with 2% microbubble contrast agents (OPTISON). Cell-impermeable calcein was used as an indicator for successful sonoporation, and propidium iodide staining was used for cell viability assessment. Peptides were also exposed to ultrasound with OPTISON and analyzed with mass spectrometry for evaluation of stability under ultrasound exposure. The effect of transduced Bak BH3 peptide was evaluated by the cell viability of successfully sonoporated cells.

resultsBak BH3 peptides did not undergo mechanical degradation with microbubble-enhanced ultrasound exposure. With the increase of acoustic energy exposure, the sonoporation efficiency saturated both in BJAB and HeLa cells, while direct cell death rate by ultrasound exposure tended to increase. When BJAB cells were treated with 100 microM Bak BH3 peptides, and ultrasound exposure with ultrasound contrast agents (OPTISON), an increased 35% cell death was confirmed. On the other hand, although HeLa cells had a similar trend, they failed to exhibit statistical significance.

conclusionsOur results suggest that microbubble-enhanced focused ultrasound peptide transduction is possible. Further optimization of ultrasound exposure conditions may be necessary.

Indexed as

MicrobubblesAntineoplastic AgentsBiological TransportBiopharmaceuticsCell DeathCell LineDrug Evaluation, PreclinicalFluoresceinsHeLa CellsHumansPropidiumSonicationTechnology, PharmaceuticalAntineoplastic AgentsFluoresceinsfluorexonPropidium

Identifiers

PMID15906165
OpenAlexW1973391358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.